Hyloris reports results for the full year 2021
Hyloris Pharmaceuticals SA (Euronext Brussels:
HYL), a specialty biopharma company committed to
addressing unmet medical needs through reinventing existing
medications, today announces its financial and operational results
for the year ending 31 December 2021.
“The past year has validated the business model
that Hyloris outlined at IPO - to deliver pragmatic and
commercially attractive medical innovations that address unmet
needs - while consistently endeavoring to grow shareholder value.
All this has occurred during a challenging period for the life
science sector.” said Stijn Van Rompay, Chief Executive
Officer of Hyloris. During the year, the company has
bolstered its emphasis on innovation and on value creation. ‘’We
retain our core focus on cost efficient development of products
through the 505(b)(2) pathway. The company has also shifted its
focus towards repurposed product candidates, adding value and
longevity to its portfolio with the addition of four exciting and
innovative product candidates. During the year, Hyloris has
invested more in in-house R&D including the opening of our
laboratory in Liege. Carrying this momentum into 2022, the company
expects to extend the reach of its commercialized products and
bring a least 4 new exciting product candidates into Hyloris.”
Increased roll out of commercial
products
Maxigesic® IV, a novel, unique combination for
the treatment of post-operative pain is currently licensed to
partners covering over 100 countries across the globe.
During 2021 and early 2022:
-
An exclusive license and distribution agreement was signed with
Hikma (LSE: HIK.L) for commercialization in the U.S. has been
signed. The PDUFA date has been set on June 30, 2022. The market
for post-operative pain is growing rapidly and is forecasted to
reach $2.6 billion by 2028 (up from $1.1 billion in 2019)1.
-
Marketing authorizations have been granted in additional countries
including: Israel, Panama, Albania, South Korea, UK, Cyprus,
France, Luxembourg, Denmark, Iceland, Ireland, Italy, Greece and
Norway.
-
Submission has been done in further countries including : Pakistan,
Oman, Bahrain, Thailand, Hong-Kong, Malaysia, US, Spain,
Netherlands, Canada and Mexico.
-
The product has been launched in 4 additional markets : Germany,
Austria, South Korea and Panama. More launches are
planned in the near future.
-
Additional patents have been granted.
________________________1 IQVIA and DelveInsight Market
Research
Sotalol IV, a novel, patented, IV formulation of
oral Sotalol for the treatment of atrial fibrillation, and
life-threatening ventricular arrhythmias developed for the
U.S.
-
Significant expansion of AltaThera’s sales force mid 2021 in order
to accelerate commercial roll-out and inclusion in hospital drug
formularies.
-
Post expansion sales performance has been impacted by COVID
19-related restrictions of access to hospitals. Mitigating measures
have been implemented.
- Currently
Sotalol IV is investigated in two clinical studies. The first study
is investigating a shorter loading regimen and is expected to be
completed in 2022. The second study is a patient registry capturing
real-world experience on loading and is expected to be completed in
2023.
4 new innovative product
candidates
Underlining the incremental lean and mean
value-creation of Hyloris, the company announced the successful
addition of four new innovative product candidates to its portfolio
during 2021. Each of the product candidates addresses a clear unmet
need and has the potential to bring substantial value to patients,
physicians and payors.
-
February 2021: Miconazole + Domiphen Bromide
(MCZ/DB): Through a development and commercialization deal
with Purna Female Healthcare, Hyloris will co-develop a topical
synergistic combination treatment for Recurrent Vulvovaginal
Candidiasis (rVVC), a condition that affects nearly 10 % of women
during their lifetime. MCZ/DB has a strong scientific and business
rationale. A Phase 2 clinical trial is ongoing with results
expected in H2 2022.
-
October 2021: CRD-102 (modified release Milrinone
capsule): a novel, clinical-stage, extended-release long
term use Milrinone capsule in late-stage heart failure (HF)
patients with an implanted left ventricular assist device (LVAD).
Heart failure is a severe and chronic condition in which the heart
muscle is unable to pump enough blood to meet the body’s need for
blood and oxygen. Earlier studies have demonstrated that treatment
with CRD-102 resulted in improved quality of life and functional
status of late-stage HF patients and it has the potential to
address the current unmet needs of late-stage LVAD patients with
right HF. Orphan drug designation has been granted in the US.
-
November 2021: Plecoid agents: Through its global
exclusive co-development rights and future joint commercialization
rights with Pleco Therapeutics, Hyloris will co-develop a chelating
agent or agents - chemical compounds that capture metal ions - to
detoxify the cancer promoting cellular micro-environment and
improve the effectiveness of chemotherapy in patients with acute
myeloid leukemia (AML: 160,000 patients2 globally) and small cell
lung cancer (SCLC: which accounts for approximately 13-15%3 of 2
million cases of lung cancer per year). Previous studies
demonstrate that elevated levels of toxic metals are associated
with inferior survival in patients with AML. Exploratory clinical
studies are currently ongoing in AML patients to evaluate the metal
rebalancing effect of chelating agents administered concomitantly
with chemotherapy.
-
December 2021: Alenura™: Hyloris’ strategic
collaboration with Vaneltix Pharma aims to develop and
commercialize AlenuraTM, a patented, innovative, clinical-stage
bladder instillation product candidate that combines lidocaine4 in
a new alkalinized form with heparin. Thanks to the novel dual
mode-of-action, AlenuraTM has the unique potential to i)
immediately relieve pain, and ii) augment the mucous layer of the
bladder. The product candidate treats acute pain in
interstitial cystitis/bladder pain syndrome (IC/BPS), a condition
that affects at least 6 million5 people in the US. Currently, there
are 3 million instillation procedures per year in the US. A Phase 2
clinical trial is expected to start by mid-2022 with results
potentially available by late 2023.
Repurposing and
reformulation
These new innovative product candidates added in
2021 reflect a continued shift in emphasis for Hyloris on
repurposing of existing drugs reaching beyond reformulation.
Repurposing is the development of a pharmaceutical product, based
on a well know molecule, but in a completely new indication.
Repurposing can have important business advantages, it represents a
more robust business strategy which is anchored in the demands of
the healthcare system that are reflected in the unmet medical needs
of patients, physicians and payors.
________________________2 Datamonitor Healthcare
April 2021; Leukemia & Lymphoma Society, 2019; WHO
classification of AML, 20163 Medscape - Abid Irshad,
MD Associate Professor, Department of Radiology, Medical
University of South Carolina College of Medicine4 Lidocaine is a
local anesthetic that works by causing temporary numbness/loss of
feeling in the skin and mucous membranes; Heparin is a component of
the mucous layer of the bladder wall and is an anticoagulant (blood
thinner) that prevents the formation of blood clots5 Data on the
female population is from the RAND Study: J Urol. 2011 August,
186(2): 540–544. doi:10.1016/j.juro.2011.03.132 Data on the male
population is from the RICE Study: J Urol. 2013 January, 189(1):
141–145. doi:10.1016/j.juro.2012.08.0
Development pipeline
The company opened its own laboratory facilities
in Liège, Belgium, bringing drug formulation and analytical
activities in-house to further streamline processes and
accelerating the R&D activities.
Hyloris has 15 products in development6 of which
two are commercialized. For all current 505(b)2 products, we have
made significant progress in 2021. Some of the achievements,
milestones and adjustments are noted below.
Hyloris expanded the commercial potential of
Tranexamic RTU beyond the U.S. with licensing deals in Australia,
New Zealand and Canada, realizing an upside that was not
anticipated at the IPO. In the US, Hyloris will optimize the
go-to-market model for Tranexamic RTU by positioning it as a
generic product, which significantly reduces regulatory costs but
resulting in later approval. Although it remains an added
value product outside of the US, it will be reported as established
market product candidate.
Hyloris obtained a worldwide exclusive license
related to an Aspirin IV formulation and technology, bringing
forward the development timeline of Aspirin IV in acute coronary
syndrome. The Aspirin IV pivotal PK study is currently ongoing.
HY-004: Phase 1 study completed with top line
results becoming available in Q2 2022. As the product moves towards
its pivotal study, the company may seek to expand and optimize the
label claims to increase the commercial potential of the product
through further evolving regulatory and clinical strategies that
could extend the timeline.
Miconazole/Domiphen Bromide: A Phase 2 clinical
trial ongoing with results expected in H2 2022.
Atomoxetine OS: Implementing changes to taste
masking technology as per FDA scientific advice received.
HY-029: Scientific advice from the regulatory
agency has been requested with the aim to start a pivotal PK
study.
For the established market product candidates,
patient recruitment for the Fusidic Acid Cream trial is ongoing in
multiple territories and the company is evaluating its response to
an FDA request relating to HY-016 for additional clinical data.
COVID-19-related restrictions affected several
of the company’s programs during 2021 with minor impacts on
timelines. None of these timeline revisions is expected to impact
substantially on the company's cash position or financial
projections. The development pipeline of added value products
currently has no direct exposure relating to the current
geopolitical situation in Eastern Europe.
________________________6 Excluding high barrier
generic products, HY-038, HY-016 and Fusidic Acid Cream
Management and Board
changes
Hyloris' strengthened its senior management team
during 2021. Thomas Jacobsen was appointed as Chief Business
Development Officer in February, and Jean-Luc Vandebroek joined as
Chief Financial Officer in September.
The company also appointed Chris Buyse as an
independent member of the Board of Directors. Chris is an
experienced investor, currently Managing Director of Fund+, the
largest Belgian life science venture capital fund.
Outlook 2022
During 2022 Hyloris anticipates delivering on
key value inflection milestones within its strategic focus areas,
including conducting 6 clinical studies on its pipeline products,
the further roll out of its commercial products and the addition of
at least 4 new product candidates through internal innovation,
in-licensing or joint ventures.
With cash and cash equivalents of €50 million at
30 December 2021, the Company is well-capitalized to advance all
current pipeline assets as planned and execute its current business
plan with the expectation to expand the portfolio to about 30
candidate and marketed products by 2024.
Conference Call
The Company will host a conference call and webcast, conducted
in English, to present the results, followed by a live Q&A
session.
The webcast will be held on 16 March 2022 at 2pm CET / 1pm GMT /
9am EST. To join the webcast, please pre-register here.
To dial-in for the conference call, please use the following
details:
US: 877-407-0792
International: +1 -201-689-8263
Conference ID: 13727870
FINANCIAL HIGHLIGHTS 2021
|
Year ended 31 December |
|
(in € thousand) |
2021 |
2020 |
Variance |
Revenues |
3,096 |
175 |
1,669% |
Research and development expenses |
(5,056) |
(3,413) |
48% |
General and administration expenses |
(2,900) |
(2,194) |
32% |
Shares’ issuance related expenses |
- |
(1,468) |
|
Other operating income/expenses |
(5,381) |
21 |
|
Operating result |
(10,541) |
(7,025) |
(50%) |
Net financial result |
(741) |
(120) |
518% |
Income Taxes |
(297) |
|
- |
Net result |
(11,579) |
(7,145) |
(62%) |
Net operating cash flow |
(11,692) |
(4,570) |
(156%) |
Cash and cash equivalents |
50,012 |
64,399 |
(22%) |
FINANCIAL REVIEW
2021Income statementIn 2021, total
revenues increased to €3.10 million versus €0.18 million in 2020,
driven by the strong growth from out-licensing Maxigesic® IV by our
partner AFT Pharmaceuticals and a continuously increasing royalties
received from AltaThera on net sales from Sotalol IV.Cost of sales
amounts to €0.11 million versus €0.15 million in 2020 and is mainly
due to fees paid to Academic Pharmaceuticals in relation to sales
of Sotalol IV and amortization expenses of the capitalized
development costs of commercialized products.
Research and development expenses increased to
€5.06 million in 2021 versus €3.41 million in 2020, in line with
the progression and the expansion of the product candidates
pipeline and the enlargement of the research and development
team.
General and administrative expenses increased to
€2.90 million in 2021 versus €2.19 million in 2020, primarily
driven by the strengthening of the management team of the
Company.
In 2021, the Company successfully renegotiated
and unwound several license agreements with the Alter Pharma Group
for the following products: Maxigesic® IV, HY-075, HY-038 and the
high-barrier generic Fusidic Acid Cream for the Canadian market.
Renegotiating and unwinding resulted in a one-time other operating
expense of €5.77 million.
As a result, the operating loss increased in
2021 to €10.54 million versus an operating loss of €7.03 million in
2020.
The net financial loss in 2021 was €0.74 million
(2020: €0.12 million). Financial income amounted to €0.32 million,
comprising mostly of interest received on deposits, versus €0.90
million last year. The figure in 2020 had been positively impacted
by non-recurring gains from the extension of the maturity of the
Shareholders loans (€0.53 million). Financial expenses amounted to
€0.77 million versus €1.02 million in 2020 and comprised mostly
interest expenses on shareholders loans and exchange
differences.
As a result, net losses in 2021 increased to
€11.58 million versus €7.15 million in 2020.
Statement of financial
positionThe Company’s non-current assets mainly consist of
(1) investments in joint ventures of € 4.1 million at year-end 2021
and (2) intangible assets of €2.94 million at year-end 2021
including capitalized development, purchased assets and
in-licensing costs, versus €2.38 million in 2020.
The Company’s current assets mainly consist of
€50.01 million in cash and cash equivalents on total assets of €
63.44 million, and trade and other receivables of € 2.32 million
primarily resulting from out-licensing revenue from Maxigesic®
IV.
Current liabilities mainly comprise
shareholders’ loans of € 11.82 million with maturity date end of
December 2022.
The Company’s equity decreased to €48.06
million, mainly as a result of the net loss for the year of € 11.58
million.
Cash flow statementNet cash
outflow from operating activities was €11.25 million in 2021,
compared to €4.57 million in 2020. The cash outflows related to
operating activities in 2021 amounted to €10.48 million (2020:
€4.60 million).
Net cash outflow from investing activities was
€2.13 million in 2021, compared to €0.63 million in 2020, and
mainly related to investments in joint ventures and capitalization
of development expenses.
The financing activities amounted to a net cash
outflow of €1.00 million in 2021 compared to a net cash inflow of
€69.40 million in 2020 from the net proceeds of the successful IPO
on Euronext Brussels in June 2020 and the convertible bonds issued
in March and April 2020.
As at 31 December 2021, cash and cash
equivalents amounted to €50.01 million, down from €64.40 million at
the end of 2020 as a result of progression and the expansion of the
product candidates pipeline, and the successful renegotiation and
unwinding of the license agreements with the Alter Pharma Group for
lead product candidates of about €5.25 million.
CONSOLIDATED STATEMENT OF FINANCIAL
POSITION FOR THE YEAR ENDED DECEMBER 31
ASSETS |
31-Dec |
|
31-Dec |
|
(in € thousand) |
2021 |
|
2020 |
|
Non-current assets |
9,485 |
|
2,569 |
|
Intangible assets |
2,944 |
|
2,381 |
|
Property, plant and equipment |
122 |
|
24 |
|
Right-of-use assets |
173 |
|
152 |
|
Investments in associates and joint ventures |
4,097 |
|
- |
|
Financial assets |
453 |
|
12 |
|
Other non-current assets |
1,714 |
|
- |
|
Current assets |
53,959 |
|
66,613 |
|
Inventories |
- |
|
- |
|
Trade and other receivables |
2,321 |
|
253 |
|
Other financial assets |
528 |
|
7 |
|
Other current assets |
1,098 |
|
1,954 |
|
Cash and cash equivalents |
50,012 |
|
64,399 |
|
TOTAL ASSETS |
63,444 |
|
69,182 |
|
|
|
|
|
|
EQUITY AND LIABILITIES |
31-Dec |
|
31-Dec |
|
(in € thousand) |
2021 |
|
2020 |
|
Equity |
48,056 |
|
59,059 |
|
Share capital |
129 |
|
129 |
|
Share premium |
103,693 |
|
103,693 |
|
Retained earnings |
-54,805 |
|
-43,226 |
|
Other reserves |
-960 |
|
-1,537 |
|
Liabilities |
15,388 |
|
10,123 |
|
Non-current liabilities |
409 |
|
7,991 |
|
Borrowings |
109 |
|
106 |
|
Other financial liabilities |
300 |
|
7,885 |
|
Current liabilities |
14,924 |
|
2,132 |
|
Current borrowings |
65 |
|
46 |
|
Other current financial liabilities |
11,815 |
|
409 |
|
Trade and other liabilities |
2,749 |
|
1,629 |
|
Current tax liabilities |
349 |
|
47 |
|
TOTAL EQUITY AND LIABILITIES |
63,444 |
|
69,182 |
|
CONSOLIDATED STATEMENT OF PROFIT OR LOSS
AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED DECEMBER
31
|
31-Dec |
|
31-Dec |
|
(in € thousand) |
2021 |
|
2020 |
|
Revenues |
3,096 |
|
175 |
|
Cost of sales |
(107 |
) |
(145 |
) |
Gross profit |
2,988 |
|
30 |
|
Research and development expenses |
(5,056 |
) |
(3,413 |
) |
General and administrative expenses |
(2,900 |
) |
(2,194 |
) |
Shares issuance related expenses |
0 |
|
(1,468 |
) |
Earnings/losses from Associates and joint ventures |
(191 |
) |
|
Other operating income |
389 |
|
21 |
|
Other operating expenses |
(5,770 |
) |
- |
|
Operating profit/(loss) (EBIT) |
(10,541 |
) |
(7,025 |
) |
Financial income |
32 |
|
901 |
|
Financial expenses |
(773 |
) |
(1,021 |
) |
Profit/(loss) before taxes |
(11,282 |
) |
7,145 |
|
Income taxes |
(297 |
) |
(1 |
) |
PROFIT/(LOSS) FOR THE PERIOD |
(11,579 |
) |
(7,145 |
) |
Other comprehensive income |
- |
|
- |
|
TOTAL COMPREHENSIVE INCOME OF THE PERIOD |
(11,579 |
) |
(7,145 |
) |
|
|
|
Profit/(loss) for the period attributable to the owners of the
Company |
(11,579 |
) |
(7,145 |
) |
Profit/(loss) for the period attributable to the non-controlling
interests |
|
- |
|
|
|
|
Total comprehensive income for the period attributable to the
owners of the Company |
(11,579 |
) |
(7,145 |
) |
Total comprehensive income for the period attributable to the
non-controlling interests |
|
- |
|
|
|
|
Basic and diluted earnings/(loss) per share (in €) |
(0.45 |
) |
(0.33 |
) |
CONSOLIDATED STATEMENT OF CHANGES IN
EQUITY FOR THE YEAR ENDED DECEMBER 31
|
Attributable to equity holders of the Company |
TotalEquity |
|
|
Sharecapital |
|
Sharepremium |
|
|
|
Other reserves |
Retainedearnings |
|
|
(in € thousand) |
|
|
|
|
Share basedpayment reserve |
|
Cost ofCapital |
|
Otherreserves |
|
|
|
Balance at 31 December 2019 |
89 |
|
23,982 |
|
1,329 |
|
- |
|
493 |
|
(36,081 |
) |
(10,188 |
) |
Initial public offering |
30 |
|
64,363 |
|
|
|
(3,725 |
) |
- |
|
- |
|
60,668 |
|
Issuance of convertible bonds |
|
|
|
|
|
|
- |
|
4,531 |
|
|
4,531 |
|
Conversion of convertible bonds |
10 |
|
15,347 |
|
|
|
(102 |
) |
(4,585 |
) |
- |
|
10,671 |
|
Amortised costs on shareholders loans |
- |
|
- |
|
|
|
- |
|
37 |
|
- |
|
37 |
|
Share-based payments |
- |
|
- |
|
485 |
|
- |
|
- |
|
- |
|
485 |
|
Total comprehensive income |
- |
|
- |
|
|
|
|
- |
|
(7,145 |
) |
(7,145 |
) |
Balance at 31 December 2020 |
129 |
|
103,693 |
|
1,814 |
|
(3,827 |
) |
476 |
|
(43,226 |
) |
59,059 |
|
|
|
|
|
|
|
|
|
|
|
|
Balance at 31 December 2020 |
129 |
|
103,693 |
|
1,814 |
|
(3,827 |
) |
476 |
|
(43,226 |
) |
59,059 |
|
Share-based payments |
- |
|
- |
|
576 |
|
- |
|
- |
|
- |
|
576 |
|
Total comprehensive income |
- |
|
- |
|
|
|
- |
|
- |
|
(11,579 |
) |
(11,579 |
) |
Balance at 31 December 2021 |
129 |
|
103,693 |
|
2,391 |
|
(3,827 |
) |
476 |
|
(54,805 |
) |
48,056 |
|
CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED
DECEMBER 31
(in € thousand) |
Note |
31-Dec |
|
31-Dec |
|
2021 |
|
2020 |
|
CASH FLOW FROM OPERATING ACTIVITIES |
|
|
|
Operating result |
|
(11,579 |
) |
(7,145 |
) |
Adjustments to reconcile net loss to net cash provided by operating
activities: |
|
|
Depreciation, amortisation and impairments |
|
137 |
|
581 |
|
Equity settled share-based payment expense |
|
576 |
|
485 |
|
Cost of equity transactions |
|
|
1,468 |
|
Interest expenses on convertible bonds |
|
|
208 |
|
Amortized costs on shareholders loans |
|
198 |
|
(139 |
) |
Borrowing costs on IPRD |
|
|
(43 |
) |
Losses from Associates and joint ventures |
|
191 |
|
|
Other non-cash adjustments |
|
(1 |
) |
(17 |
) |
Changes in working capital: |
|
|
|
Trade and other receivables |
|
(2,068 |
) |
81 |
|
Other current and non-current assets |
|
(771 |
) |
1,246 |
|
Trade and other liabilities |
|
1,138 |
|
(1,398 |
) |
Other current and non-current financial liabilities |
|
623 |
|
103 |
|
Other current and non-current liabilities |
|
301 |
|
(1 |
) |
Cash generated from operations |
|
(11,253 |
) |
(4,571 |
) |
Taxes paid |
|
3 |
|
1 |
|
Net cash generated from operating activities |
|
(11,250 |
) |
(4,570 |
) |
CASH FLOW FROM INVESTING ACTIVITIES |
|
|
|
Purchases of property, plant and equipment |
|
(107 |
) |
- |
|
Purchases of Intangible assets |
|
(954 |
) |
(623 |
) |
Proceeds (from disposal) of intangible assets |
|
219 |
|
|
Investments in associates and joint ventures |
|
(1,270 |
) |
- |
|
Acquisition of other financial assets |
|
(21 |
) |
(10 |
) |
Other |
|
|
- |
|
Net cash provided by/(used in) investing
activities |
|
(2,133 |
) |
(633 |
) |
CASH FLOW FROM FINANCING ACTIVITIES |
|
|
|
Reimbursements of borrowings and other financial liabilities |
|
|
(8,050 |
) |
Proceeds from borrowings and other financial liabilities |
|
|
3,250 |
|
Reimbursements of borrowings |
|
(62 |
) |
(51 |
) |
Repayment received from other financial assests |
|
216 |
|
|
Payment of other financial assests |
|
(1,157 |
) |
|
Net proceeds from Initial Public Offering |
|
|
59,254 |
|
Net proceeds from convertible bonds |
|
|
14,994 |
|
Net cash provided by/(used in) financing
activities |
|
(1,004 |
) |
69,397 |
|
NET INCREASE (DECREASE) IN CASH AND CASH
EQUIVALENTS |
|
(14,387 |
) |
64,194 |
|
CASH AND CASH EQUIVALENTS at beginning of the
period |
|
64,399 |
|
205 |
|
CASH AND CASH EQUIVALENTS at end of the period,
calculated |
|
50,012 |
|
64,399 |
|
AUDIT REPORTThe statutory
auditor, KPMG Bedrijfsrevisoren - Réviseurs d’Entreprises,
represented by Olivier Declercq, has confirmed that the audit
procedures, which have been substantially completed, have not
revealed any material misstatement in the accounting information
included in the Company’s annual announcement.
About Hyloris
PharmaceuticalsHyloris is a specialty biopharma company
focused on innovating, reinventing, and optimizing existing
medications to address important healthcare needs and deliver
relevant improvements for patients, healthcare professionals and
payors. Hyloris has built a broad, patented portfolio of 15
reformulated and repurposed value-added medicines that have the
potential to offer significant advantages over available
alternatives. Outside of its core strategic focus, the Company also
has 3 high barrier generic products in development and registration
phase. Two products are currently in initial phases of
commercialization with partners: Sotalol IV for the treatment of
atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative
pain treatment. The Company’s development strategy primarily
focuses on the FDA’s 505(b)2 regulatory pathway, which is
specifically designed for pharmaceuticals for which safety and
efficacy of the molecule have already been established. This
pathway can reduce the clinical burden required to bring a product
to market, and significantly shorten the development timelines and
reduce costs and risks. Hyloris is based in Liège, Belgium. For
more information, visit www.hyloris.com and follow-us
on LinkedIn.
For more information contact
:
Hyloris Pharmaceuticals, Investors and Media
investorrelations@hyloris.com
Disclaimer and forward-looking
statementsHyloris means “high yield, lower risk”, which
relates to the 505(b)(2) regulatory pathway for product approval on
which the Issuer focuses, but in no way relates or applies to an
investment in the Shares.Certain statements in this press release
are “forward-looking statements.” These forward-looking statements
can be identified using forward-looking terminology, including the
words "believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. These statements relate to future events or the Company’s
future financial performance and involve known and unknown risks,
uncertainties, and other factors, many of which are beyond the
Company’s control, that may cause the actual results, levels of
activity, performance or achievements of the Company or its
industry to be materially different from those expressed or implied
by any forward-looking statements. The Company undertakes no
obligation to publicly update or revise forward-looking statements,
except as may be required by law.
Grafico Azioni Hyloris Pharmaceuticals (EU:HYL)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Hyloris Pharmaceuticals (EU:HYL)
Storico
Da Mar 2023 a Mar 2024